Latest news and press releases about ADC Therapeutics S.A. (ADCT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-...
Price
| Price | $1.05 |
| Market Cap | $134M |
| Exchange | NYSE |
| Country | CH |
Valuation Ratios
| Price / Book | -0.56 |
| EV / EBITDA | -3.82 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 44.63% |
| Return on Invested Capital | -49.54% |
| Return on Assets | -34.69% |
| Gross Margin | 88.75% |
| Operating Margin | -125.83% |
| Net Margin | -123.03% |
Related companies: ALMS · AUTL · BCYC · FDMT · LCTX · LXRX · NMRA
Explore sector: Healthcare · Biotechnology
More sections of ADCT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks